| Patent application number | Description | Published |
|---|
| 20110064732 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 03-17-2011 |
| 20110182892 | Methods to identify responsive patients - The present invention provides methods and kits for improving the progression-free survival of a patient suffering from gastrointestinal cancer and for assessing the sensitivity or responsiveness of the patient to treatment comprising bevacizumab. | 07-28-2011 |
| 20110184004 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides biomarkers which are predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 07-28-2011 |
| 20110184005 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 07-28-2011 |
| 20110190321 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients. | 08-04-2011 |
| 20110195982 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients | 08-11-2011 |
| 20110212979 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 09-01-2011 |
| 20110218212 | PREDICTIVE MARKERS FOR EGFR INHIBITORS TREATMENT - The present invention provides biomarkers that are predictive for the response to treatment with an EGFR inhibitor in cancer patients. The markers are the genes GBAS, APOH, SCYL3, PMS2CL, PRODH, SERF1A, URG4A and LRRC31. | 09-08-2011 |
